- Home
- STI vs RLYB Comparison
STI vs RLYB Comparison
Compare STI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- RLYB
- Stock Information
- Founded
- STI 2014
- RLYB 2018
- Country
- STI United States
- RLYB United States
- Employees
- STI N/A
- RLYB N/A
- Industry
- STI
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- RLYB Health Care
- Exchange
- STI NYSE
- RLYB Nasdaq
- Market Cap
- STI 46.6M
- RLYB 42.3M
- IPO Year
- STI N/A
- RLYB 2021
- Fundamental
- Price
- STI $0.45
- RLYB $0.99
- Analyst Decision
- STI
- RLYB Buy
- Analyst Count
- STI 0
- RLYB 6
- Target Price
- STI N/A
- RLYB $8.10
- AVG Volume (30 Days)
- STI 21.7M
- RLYB 80.7K
- Earning Date
- STI 11-26-2024
- RLYB 11-07-2024
- Dividend Yield
- STI N/A
- RLYB N/A
- EPS Growth
- STI N/A
- RLYB N/A
- EPS
- STI N/A
- RLYB N/A
- Revenue
- STI $6,644.00
- RLYB $598,000.00
- Revenue This Year
- STI N/A
- RLYB N/A
- Revenue Next Year
- STI N/A
- RLYB N/A
- P/E Ratio
- STI N/A
- RLYB N/A
- Revenue Growth
- STI N/A
- RLYB N/A
- 52 Week Low
- STI $0.27
- RLYB $0.96
- 52 Week High
- STI $13.85
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- STI 59.83
- RLYB 41.20
- Support Level
- STI $0.31
- RLYB $0.98
- Resistance Level
- STI $0.43
- RLYB $1.15
- Average True Range (ATR)
- STI 0.08
- RLYB 0.07
- MACD
- STI 0.00
- RLYB 0.00
- Stochastic Oscillator
- STI 36.49
- RLYB 18.80
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.